

# Sleep Apnea and Cardiovascular Disease

Dr Ulrika Makuraj

MBBCH (WITS)

MSc Inf. Disease (LSHTM)

*“Laugh and the world laughs with you, snore and you sleep alone.”* – Anthony Burgess

# Disclosures

- Clinical Manager Sleep and Respiratory Care at Philips SA and EA
- SSEM sponsored

# Cardiovascular Physiology Overview

# Cardiovascular System Function

## 1. Transport

- Nutrients and O<sub>2</sub>
- Remove metabolic byproducts (ADP, K<sup>+</sup>, CO<sub>2</sub>)
- Hormones

## 2. Protection

- Immune cells, antibodies, complement proteins, coagulation

## 3. Regulation

- Body temperature, pH and fluids

# The Heart: Structure




Figure: Download for free at <http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@6.27>.

# The Heart: Function

## Pumping:


- Right side of the heart (RA and RV) pump blood to the lungs to be oxygenated
- Left side of the heart (LA and LV) oxygenated blood pumped out to the body supplying the fuel that cells need to function
- **Ejection fraction** determines how well your heart pumps with each beat
  - **Left ventricular ejection fraction (LVEF)** measurement of the percentage of blood is being pumped out of the left ventricle with each contraction. Commonly measured by Echocardiogram

LVEF	
≥ 55 %	Normal
45-54%	Mildly abnormal
30-44 %	Moderately abnormal (may confirm diagnosis of heart failure)
<35%	Severely abnormal

# The Heart: Function

**Endocrine** - Cardiomyocytes synthesize and secrete

- Atrial natriuretic peptide (ANP) – atria
- B-type - brain natriuretic peptide (BNP) - ventricles
  - Most sensitive and specific indicator of ventricular dysfunction
  - Used in diagnoses and prognosis in CHF



BNP levels	Interpretation
< 100 pg/mL	Normal (No heart failure)
100-400 pg/mL	Possible HF
> 500 pg/mL	Heart failure


# Cardiovascular Centers

## HR control

- Cardiovascular centers in the medulla oblongata

## Autonomic Innervation

- Sympathetic Pathways
- Parasympathetic Pathways





# The Cardiovascular System: Summary

## **Cardiovascular regulation**

- Ensures adequate circulation to body tissues

## **Cardiovascular centers**

- Control heart and peripheral blood vessels

## **Cardiovascular system responds to**

- Changing activity patterns
- Circulatory emergencies

# Cardiovascular Responses to Normal Sleep

# Autonomic responses during sleep

Sleep State-dependent changes in SNA and BP

**NREM:** Generalized cardiovascular deactivation and baroreflex resetting

- ↓ Vagal activity → ↓ HR
- ↓ Sympathetic vasomotor tone (Muscle sympathetic nerve activity (MSNA)) → ↓ BP

**REM:** BP and HR are similar to levels recorded during quiet wakefulness

- ↑ Sympathetic vasomotor tone (MSNA)
- Transient baroreflex suppression
- Fluctuations in HR


# Cardiovascular Responses During Sleep in OSA patients

# Blood Pressure and sympathetic activity during obstructive apnea events

Prospective study comparing OSA to non-OSA patients has shown:

Patients with OSA

- high levels of sympathetic nerve activity (SNA) even when awake
- Blood pressure and sympathetic nerve activity did not fall during any stage of sleep.




# Nocturnal blood pressure profile

## 24 hr. ambulatory blood pressure monitoring

### Normotensive Non-OSA patient


Dipping pattern of nocturnal BP (17% reduction in mean arterial pressure)



Gardner SF et al, J Am Board Fam Pract 2001;14:166-71.)


### Newly diagnosed OSA

Non-dipping pattern of nocturnal BP possibly due to exaggerated sympathetic nervous system activity



Rimoldi SF et al, Eur. Heart J. 2014;35(19):1245-1254

# Pathophysiologic events in OSA



↓ oxyhemoglobin saturation



Stimulation of peripheral chemoreceptors



Central Nervous system stimulation




↑ Sympathetic vasomotor tone




↑ Arterial blood pressure

# Effects of OSA on the Right and Left Ventricle





# Cardiovascular Autonomic Effects of OSA




# Sleep Apnea and Cardiovascular Diseases

SA is strongly associated with a number of CVDs including :

- Hypertension
- Resistant HTN
- Transient ischemic attack
- Stroke
- Pulmonary hypertension
- Heart Failure
- Coronary Heart Disease
- Atrial Fibrillation
- Myocardial ischemia
- Myocardial infarction
- Sudden death




The prevalence is even higher in those suffering from cardiovascular diseases




# Heart Failure(HF)

- Presence of sleep-disordered breathing is recognized as one of the factors contributing to the excess morbidity and mortality in HF
- Central sleep apnea is highly prevalent in HF: 30% to 50% of patients
- Respiratory instability in HF lead to the rhythmic pattern of breathing referred to as Cheyne-Stokes Breathing (CSB)
- CSB - recurrent cycles of smooth and gradual crescendo–decrescendo changes in tidal volume with an intervening central apnea in a patient with HF
- CSB is unique to patients with HF as it has a long cycle time reflecting the prolonged circulation time- a pathological feature of heart failure with reduced ejection fraction

# Mechanisms leading to periodic breathing in HF



# Pathophysiologic Consequences of CSA in HF



# Servo ventilation: CSA in HF

## **SERVE-HF trial**

International, multicenter (91), randomized, parallel-group, event-driven study

- N= 1325 patients, follow-up 2 years.
- Symptomatic chronic systolic HF (LVEF  $\leq$ 45%)
- AHI  $\geq$ 15 events/h, predominantly CSA
- Intervention: Optimal cardiac therapy with or without ASV
- Primary combined end-point: Time to first event of
  - Death from any cause, life-saving cardiovascular intervention\*, or unplanned hospitalization for worsening heart failure

## **Results**


- No difference in primary endpoint.
- All-cause mortality and cardiovascular mortality significantly higher under ASV

# SERVE-HF trial - Summary

- Bias due to unblinded study design
- The study was conducted in patients who had heart failure with reduced ejection fraction, and therefore the results can NOT be generalized to patients who have heart failure with preserved ejection fraction
- The study results also can NOT be extrapolated to patients with predominantly obstructive sleep apnea
- Addition of adaptive servo-ventilation to guideline based medical treatment did not improve the outcome **in patients with HFrEF and CSA** despite effective control of CSA

# CSA/CSR in Heart Failure

## Suggested PAP Therapy Protocol



Developed by Prof. Dr. Winfried Randerath

Ayas NT et al. AJRCCM 2015 192(2): 132-133 AASM (2015). "Special Safety Notice: ASV therapy for central sleep apnea patients with heart failure."  
<http://www.aasmnet.org/articles.aspx?id=5562>.



# Hypertension (HTN)

- Causal link between OSA and systemic hypertension has been established
- Several studies have shown that sleep apnea increases the relative risk for hypertension, independent of other confounding factors
- **Treatment:** CPAP therapy and lifestyle modification
- Studies using 24-h BP monitoring consistently report drops of 2 to 2.5 mm Hg and 1.5 to 2 mm Hg in systolic blood pressure and diastolic blood pressure, respectively, compared with subtherapeutic or conservative treatment, with greater reductions in patients with resistant HTN (between 4.7 to 7.2 mm Hg and 2.9 to 4.9 mm Hg for SBP and DBP, respectively)
- CPAP has also been demonstrated to reverse nondipper or riser nocturnal BP patterns in OSA patients

# Pulmonary Hypertension (PHTN)

- About 10% of patients with OSA have PHTN (defined as the mean pulmonary artery pressure  $\geq 25$  mm Hg)
- **Treatment:** Multiple observational studies demonstrate that treating OSA with CPAP improves PHTN
- In the only small randomized crossover study (therapeutic vs. sham CPAP), 12 weeks of treatment resulted in a significant decrease in pulmonary artery systolic pressure (from a mean of 30 to 24 mm Hg)
- The reduction was greatest (8.5 mm Hg) in patients with baseline PHTN (pulmonary artery systolic pressure  $\geq 30$  mm Hg by echocardiography)
- The American College of Cardiology/American Heart Association expert consensus document recommends polysomnography to rule out OSA for all patients with PHTN

# TIA/Stroke

- Sleep apnea is highly prevalent in patients with stroke or TIA
- OSA also is associated with increased risk for incident stroke
- **Treatment** : CPAP therapy
- There is some evidence that early CPAP therapy has positive effects on long-term survival in ischemic stroke patients with moderate-to-severe OSA
- The American Heart Association/American Stroke Association guideline states: “A sleep study might be considered for patients with an ischemic stroke or TIA on the basis of the very high prevalence of sleep apnea in this population and the strength of the evidence that the treatment of sleep apnea improves outcomes in the general population”

# Arrhythmias

- Cardiac arrhythmias are common problems in OSA patients
- Individuals with severe SDB are two- to four-times more likely to develop complex arrhythmias than those without SDB
- 49% of patients with atrial fibrillation have OSA compared with 32% in general cardiology practice
- **Treatment** : CPAP treatment is associated with a significantly decreased recurrence rate of AF, even after electrical cardioversion or ablative therapies
- Patients are less likely to progress to more permanent forms of AF and have significantly reduced occurrence of paroxysmal AF compared with untreated patients

# Summary


- Adequately treated OSA has been associated with improved cardiovascular outcomes
- Patients with untreated OSA were 2.68 times more likely to suffer a non-fatal CV event compared to those whose OSA was effectively treated with CPAP
- Patients with untreated OSA were 2.5 times more likely to suffer a fatal CV event compared to those whose OSA was effectively treated with CPAP

# References

1. Berne R, Levy M. *Cardiovascular Physiology*. 8th ed. St. Louis, Missouri: Mosby; 2001.
2. Okada H, Iwase S, Mano T, Sugiyama Y, Watanabe T. Changes in muscle sympathetic nerve activity during sleep in humans. *Neurology*. 1991;41(12):1961-1966.
3. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. *J. Clin. Invest.* 1995;96(4):1897-1904.
4. Somers VK, Abboud FM. Chemoreflexes--responses, interactions and implications for sleep apnea. *Sleep*. 1993;16(8 Suppl):S30-33; discussion S33-34.
5. Gardner SF, Schneider EF. 24-Hour ambulatory blood pressure monitoring in primary care. *J Am Board Fam Pract* . 2001;14(3):166-171.
6. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? *Eur. Heart J.* 2014;35(19):1245-1254.
7. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. *J. Am. Coll. Cardiol.* 2011;57(2):119-127.
8. Yumino D, Bradley TD. Central sleep apnea and Cheyne-Stokes respiration. *Proc. Am. Thorac. Soc.* 2008;5(2):226-236.
9. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. *Lancet*. 2009;373(9657):82-93.
10. Kim H-N, Januzzi JL. Natriuretic Peptide Testing in Heart Failure. *Circulation*. 2011;123(18):2015-2019.
11. Solomon S, Wu J, Gillam L, Bulwer B. Echocardiography In: Mann DL, Zipes D, Libby P, Bonow R, Braunwald E eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 10 ed: Elsevier; 2015.

Questions???

## CENTRAL ILLUSTRATION: Potential Etiological Risk Factors for Sleep Apnea and the Downstream Consequences



Javaheri, S. et al. J Am Coll Cardiol. 2017;69(7):841-58.



# SERVE-HF vs ADVENT-HF trial

	SERVE- HF	ADVENT HF
Type of SDB	Predominantly CSA	Non sleepy OSA (64%)
Device algorithm	Did not allow lower end-exp pressure and min PS (5-3 cmH2O)	Lower default end-exp pressure and min PS ( 4 - 0 cmH2O)
ASV titration	<b>Not centrally reviewed</b>	Reviewed centrally *
ASV adherence	3.4 h/night	> 1 hour higher*
Nasal mask	15%	78%
Follow up	yearly	2x year
DSMB	<b>Reviewed data 2x in 7 years</b>	Every 6 months

\*Device pressure setting prescribed by the core sleep laboratory to maintain the lowest pressures possible